AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 281: H647-H654, 2001;
0363-6135/01 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (51)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Delyani, J. A.
Right arrow Articles by Rudolph, A. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Delyani, J. A.
Right arrow Articles by Rudolph, A. E.
Vol. 281, Issue 2, H647-H654, August 2001

Effect of a selective aldosterone receptor antagonist in myocardial infarction

John A. Delyani, Eric L. Robinson, and Amy E. Rudolph

Cardiovascular and Metabolic Diseases, Pharmacia Corporation, St. Louis, Missouri 63141

Myocardial infarction (MI) initiates adaptive tissue remodeling, which is essential for heart function (such as infarct healing) but is also important for maladaptive remodeling (for example, reactive fibrosis and left ventricular dilation). The effect of aldosterone receptor antagonism on these processes was evaluated in Sprague-Dawley rats using eplerenone, a selective aldosterone receptor antagonist. Infarct healing and left ventricular remodeling were evaluated at 3, 7, and 28 days after MI by determination of the diastolic pressure-volume relationship of the left ventricle, the infarct-thinning ratio, and the collagen-volume fraction. Eplerenone did not affect reparative collagen deposition as was evidenced by a similar collagen volume fraction in the infarcted myocardium between eplerenone and vehicle-treated groups at 7 and 28 days post-MI. In addition, the thinning ratio, which is an index of infarct expansion, was comparable between the eplerenone and vehicle-treated animals at 7 and 28 days post-MI. A protective effect of eplerenone was demonstrated at 28 days post-MI, where reactive fibrosis in the viable myocardium was reduced in eplerenone-treated animals compared with vehicle-treated animals. Thus aldosterone receptor antagonism does not retard infarct healing but rather protects against maladaptive responses after MI.

fibrosis; left ventricular remodeling; eplerenone


This article has been cited by other articles:


Home page
 Eur J Heart FailHome page
C. Adamopoulos, A. Ahmed, R. Fay, M. Angioi, G. Filippatos, J. Vincent, B. Pitt, F. Zannad, and the EPHESUS Investigators
Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial
Eur J Heart Fail, November 1, 2009; 11(11): 1099 - 1105.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
B. R. Palmer, A. P. Pilbrow, C. M. Frampton, T. G. Yandle, L. Skelton, M. G. Nicholls, and A. M. Richards
Plasma aldosterone levels during hospitalization are predictive of survival post-myocardial infarction
Eur. Heart J., October 2, 2008; 29(20): 2489 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
H. Matsusaka, T. Ide, S. Matsushima, M. Ikeuchi, T. Kubota, K. Sunagawa, S. Kinugawa, and H. Tsutsui
Targeted deletion of p53 prevents cardiac rupture after myocardial infarction in mice
Cardiovasc Res, June 1, 2006; 70(3): 457 - 465.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
S Enomoto, M Yoshiyama, T Omura, R Matsumoto, T Kusuyama, S Kim, Y Izumi, K Akioka, H Iwao, K Takeuchi, et al.
Effects of eplerenone on transcriptional factors and mRNA expression related to cardiac remodelling after myocardial infarction
Heart, December 1, 2005; 91(12): 1595 - 1600.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi
Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure
Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
B. Pitt, H. White, J. Nicolau, F. Martinez, M. Gheorghiade, M. Aschermann, D. J. van Veldhuisen, F. Zannad, H. Krum, R. Mukherjee, et al.
Eplerenone Reduces Mortality 30 Days After Randomization Following Acute Myocardial Infarction in Patients With Left Ventricular Systolic Dysfunction and Heart Failure
J. Am. Coll. Cardiol., August 2, 2005; 46(3): 425 - 431.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
B. Pitt
Aldosterone Blockade in Patients With Acute Myocardial Infarction
Circulation, May 27, 2003; 107(20): 2525 - 2527.
[Full Text] [PDF]

Home page
 NEJMHome page
B. Pitt, W. Remme, F. Zannad, J. Neaton, F. Martinez, B. Roniker, R. Bittman, S. Hurley, J. Kleiman, M. Gatlin, et al.
Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction
N. Engl. J. Med., April 3, 2003; 348(14): 1309 - 1321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
J. R. R. Heyen, E. R. Blasi, K. Nikula, R. Rocha, H. A. Daust, G. Frierdich, J. F. Van Vleet, P. De Ciechi, E. G. McMahon, and A. E. Rudolph
Structural, functional, and molecular characterization of the SHHF model of heart failure
Am J Physiol Heart Circ Physiol, November 1, 2002; 283(5): H1775 - H1784.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online